NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Lonza today announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire. Financial terms were not disclosed.
Biologic medicines that treat serious diseases are an integral part of Bristol-Myers Squibb’s specialty care portfolio and R&D pipeline. Bristol-Myers Squibb and Lonza have been collaborating since 2003 to produce commercial supplies of a biologics medicine marketed by Bristol-Myers Squibb worldwide. Currently, Lonza also produces clinical supplies of an investigational biologics medicine for Bristol-Myers Squibb.
“Our expanded relationship with Lonza is an important example of our global manufacturing strategy to meet anticipated demand for our commercial biologics portfolio and prepare to bring our late-stage clinical assets to patients by supplementing our in-house manufacturing capabilities,” said Lou Schmukler, president, Global Manufacturing & Supply, Bristol-Myers Squibb.
Lonza’s development and manufacturing facilities offer proven expression systems and established platform processes for streamlined scale-up throughout the clinical pipeline. In addition to its state-of-the-art Portsmouth facility, Lonza offers three additional clinical-to-commercial mammalian production facilities in Tuas, Singapore; Porrino, Spain; and Slough, United Kingdom.
“We are pleased to extend our relationship with Bristol-Myers Squibb for the commercial production of their innovative drug substance, said Marc Funk, COO of Lonza’s Pharma & Biotech Segment. “This reinforces Lonza’s mission to support life-saving medicines by being a reliable supplier of drug substance for our customers with high-quality commercial GMP manufacturing services delivered to the market.”
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma & Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
Contacts
Bristol-Myers Squibb
Media:
Laura Hortas, +1 609-252-4587
laura.hortas@bms.com
or
Frederick Egenolf, +1 609-252-4875
frederick.egenolf@bms.com
or
Investors:
Ranya Dajani, +1 609-252-5330
ranya.dajani@bms.com
or
Ryan Asay, +1 609-252-5020
ryan.asay@bms.com
or
Lonza
Media:
Dominik Werner, +41 61 316 8798
dominik.werner@lonza.com
or
Constance Ward, +41 61 316 8840
constance.ward@lonza.com
or
Colleen Floreck, +1 201 316 9290
colleen.floreck@lonza.com
or
Investors:
Dirk Oehlers, +41 61 316 8540
dirk.oehlers@lonza.com
Help employers find you! Check out all the jobs and post your resume.
